Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavacamten in symptomatic latent obstructive hypertrophic cardiomyopathy
NCT06947590Active, not recruiting
- Start
- Apr 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of mavacamten in hypertrophic cardiomyopathy (HCM) (2 arms). Primary endpoint: Change in peak left ventricular outflow tract gradient at 30 weeks. Started Apr 2025; status: active, not recruiting.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT06947590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06947590.